Insulet [PODD] vs Edwards Lifesciences [EW] Detailed Stock Comparison
Insulet
NASDAQ
Loading...
Edwards Lifesciences
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Insulet wins in 5 metrics, Edwards Lifesciences wins in 14 metrics, with 0 ties. Edwards Lifesciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Insulet | Edwards Lifesciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 99.95 | 34.18 | Edwards Lifesciences |
| Price-to-Book Ratio | 15.77 | 4.55 | Edwards Lifesciences |
| Debt-to-Equity Ratio | 95.68 | 6.62 | Edwards Lifesciences |
| PEG Ratio | -1.13 | -5.21 | Edwards Lifesciences |
| EV/EBITDA | 49.09 | 25.56 | Edwards Lifesciences |
| Profit Margin (TTM) | 10.01% | 72.96% | Edwards Lifesciences |
| Operating Margin (TTM) | 18.66% | 28.12% | Edwards Lifesciences |
| EBITDA Margin (TTM) | 18.66% | 28.12% | Edwards Lifesciences |
| Return on Equity | 19.18% | 15.53% | Insulet |
| Return on Assets (TTM) | 7.75% | 8.42% | Edwards Lifesciences |
| Free Cash Flow (TTM) | $296.30M | $259.90M | Insulet |
| 1-Year Return | 78.76% | 15.45% | Insulet |
| Price-to-Sales Ratio (TTM) | 9.78 | 8.44 | Edwards Lifesciences |
| Enterprise Value | $23.36B | $44.49B | Edwards Lifesciences |
| EV/Revenue Ratio | 9.90 | 7.83 | Edwards Lifesciences |
| Gross Profit Margin (TTM) | 69.67% | 77.52% | Edwards Lifesciences |
| Revenue per Share (TTM) | $34 | $10 | Insulet |
| Earnings per Share (Diluted) | $3.28 | $2.39 | Insulet |
| Beta (Stock Volatility) | 1.35 | 1.08 | Edwards Lifesciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Insulet vs Edwards Lifesciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Insulet | 0.89% | 2.96% | 15.83% | 3.04% | 16.68% | 28.78% |
| Edwards Lifesciences | 0.83% | 4.56% | 7.25% | 9.41% | 12.47% | 12.73% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Insulet | 78.76% | 23.81% | 54.32% | 1,013.33% | 2,316.14% | 2,078.99% |
| Edwards Lifesciences | 15.45% | -10.31% | -2.96% | 239.26% | 745.35% | 2,179.39% |
Performance & Financial Health Analysis: Insulet vs Edwards Lifesciences
| Metric | PODD | EW |
|---|---|---|
| Market Information | ||
| Market Cap | $23.08B | $47.97B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 680,330 | 3,269,775 |
| 90 Day Avg. Volume | 639,633 | 4,546,188 |
| Last Close | $330.77 | $81.83 |
| 52 Week Range | $180.31 - $334.18 | $64.01 - $83.00 |
| % from 52W High | -1.02% | -1.41% |
| All-Time High | $335.91 (May 01, 2023) | $131.73 (Dec 27, 2021) |
| % from All-Time High | -1.53% | -37.88% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.33% | 0.12% |
| Quarterly Earnings Growth | -0.88% | -0.09% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.73% |
| Operating Margin (TTM) | 0.19% | 0.28% |
| Return on Equity (TTM) | 0.19% | 0.16% |
| Debt to Equity (MRQ) | 95.68 | 6.62 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $20.78 | $17.94 |
| Cash per Share (MRQ) | $15.93 | $6.92 |
| Operating Cash Flow (TTM) | $516.20M | $794.90M |
| Levered Free Cash Flow (TTM) | $112.66M | $1.26B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Insulet vs Edwards Lifesciences
| Metric | PODD | EW |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 99.95 | 34.18 |
| Forward P/E | 84.72 | 33.35 |
| PEG Ratio | -1.13 | -5.21 |
| Price to Sales (TTM) | 9.78 | 8.44 |
| Price to Book (MRQ) | 15.77 | 4.55 |
| Market Capitalization | ||
| Market Capitalization | $23.08B | $47.97B |
| Enterprise Value | $23.36B | $44.49B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.90 | 7.83 |
| Enterprise to EBITDA | 49.09 | 25.56 |
| Risk & Other Metrics | ||
| Beta | 1.35 | 1.08 |
| Book Value per Share (MRQ) | $20.78 | $17.94 |
Financial Statements Comparison: Insulet vs Edwards Lifesciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PODD | EW |
|---|---|---|
| Revenue/Sales | $569.00M | $1.41B |
| Cost of Goods Sold | $160.00M | $301.60M |
| Gross Profit | $409.00M | $1.11B |
| Research & Development | $59.60M | $254.60M |
| Operating Income (EBIT) | $88.80M | $409.90M |
| EBITDA | $118.50M | $461.60M |
| Pre-Tax Income | $48.10M | $433.90M |
| Income Tax | $12.70M | $70.30M |
| Net Income (Profit) | $35.40M | $356.40M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PODD | EW |
|---|---|---|
| Cash & Equivalents | $1.28B | $3.14B |
| Total Current Assets | $2.33B | $6.21B |
| Total Current Liabilities | $520.40M | $1.39B |
| Long-Term Debt | $1.61B | $675.70M |
| Total Shareholders Equity | $1.33B | $10.19B |
| Retained Earnings | $75.70M | $13.53B |
| Property, Plant & Equipment | N/A | $1.80B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PODD | EW |
|---|---|---|
| Operating Cash Flow | $81.00M | $294.00M |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | $48.10M | $224.40M |
| Debt Repayment | $-182.70M | N/A |
| Common Stock Repurchase | N/A | $-258.60M |
Short Interest & Institutional Ownership Analysis
| Metric | PODD | EW |
|---|---|---|
| Shares Short | 1.75M | 8.00M |
| Short Ratio | 3.03 | 1.69 |
| Short % of Float | 0.04% | 0.02% |
| Average Daily Volume (10 Day) | 680,330 | 3,269,775 |
| Average Daily Volume (90 Day) | 639,633 | 4,546,188 |
| Shares Outstanding | 70.20M | 588.60M |
| Float Shares | 70.08M | 581.11M |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 1.02% | 0.89% |
Dividend Analysis & Yield Comparison: Insulet vs Edwards Lifesciences
| Metric | PODD | EW |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |